Study

Genomic analysis of Smoothened inhibitor resistance in basal cell carcinoma

Study ID Alternative Stable ID Type
EGAS00001000845 Other

Study Description

Smoothened inhibitors are currently being investigated for the treatment of several cancers. Vismodegib is approved for the treatment of locally advanced and metastatic basal cell carcinoma (BCC). The majority of BCC patients treated with vismodegib experience significant clinical benefit, however, a small number of patients develop resistance. Knowledge of resistance mechanisms can generate predictive biomarkers and is critical for the design of additional therapeutic strategies aimed at circumventing resistance. To investigate mechanisms of resistance to vismodegib in BCC we sequenced and profiled biopsies from patients who initially responded to treatment and subsequently progressed on drug.We find that resistance is associated with re-activation of the Hedgehog (Hh) pathway through diverse mechanisms, including concurrent copy number alterations in the downstream Hh pathway components SUFU and GLI2, as well as novel SMO mutations that reduce sensitivity to vismodegib. The latter fall into two classes: those that activate SMO and those that directly affect the vismodegib-binding ... (Show More)

Study Datasets 5 datasets.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001000881
RNA sequencing of Resistant BCC samples.
Illumina HiSeq 2000 11
EGAD00001000887
Exome sequencing of Resistant BCC samples.
Illumina HiSeq 2000 23
EGAD00001001125
Exome sequencing of Untreated BCC samples.
Illumina HiSeq 2000 91
EGAD00010000678
Tumor sample SNP arrays
Illumina SNP array 11
EGAD00010000680
Tumor sample CGH arrays
Agilent CGH array 4

Who archives the data?

Publications

Citations

Retrieving...
Retrieving...
Retrieving...
Retrieving...